177 related articles for article (PubMed ID: 18708367)
1. Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.
Markovina S; Callander NS; O'Connor SL; Kim J; Werndli JE; Raschko M; Leith CP; Kahl BS; Kim K; Miyamoto S
Mol Cancer Res; 2008 Aug; 6(8):1356-64. PubMed ID: 18708367
[TBL] [Abstract][Full Text] [Related]
2. Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma.
Huynh M; Pak C; Markovina S; Callander NS; Chng KS; Wuerzberger-Davis SM; Bakshi DD; Kink JA; Hematti P; Hope C; Asimakopoulos F; Rui L; Miyamoto S
J Biol Chem; 2018 Feb; 293(7):2452-2465. PubMed ID: 29279332
[TBL] [Abstract][Full Text] [Related]
3. Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.
Chen Z; Ricker JL; Malhotra PS; Nottingham L; Bagain L; Lee TL; Yeh NT; Van Waes C
Mol Cancer Ther; 2008 Jul; 7(7):1949-60. PubMed ID: 18645005
[TBL] [Abstract][Full Text] [Related]
4. Silencing of SENP2 in Multiple Myeloma Induces Bortezomib Resistance by Activating NF-κB Through the Modulation of IκBα Sumoylation.
Xie H; Gu Y; Wang W; Wang X; Ye X; Xin C; Lu M; Reddy BA; Shu P
Sci Rep; 2020 Jan; 10(1):766. PubMed ID: 31964975
[TBL] [Abstract][Full Text] [Related]
5. Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells.
Meister S; Frey B; Lang VR; Gaipl US; Schett G; Schlötzer-Schrehardt U; Voll RE
Neoplasia; 2010 Jul; 12(7):550-61. PubMed ID: 20651984
[TBL] [Abstract][Full Text] [Related]
6. Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma.
Franqui-Machin R; Hao M; Bai H; Gu Z; Zhan X; Habelhah H; Jethava Y; Qiu L; Frech I; Tricot G; Zhan F
J Clin Invest; 2018 Jul; 128(7):2877-2893. PubMed ID: 29863498
[TBL] [Abstract][Full Text] [Related]
7. The clinically approved proteasome inhibitor PS-341 efficiently blocks influenza A virus and vesicular stomatitis virus propagation by establishing an antiviral state.
Dudek SE; Luig C; Pauli EK; Schubert U; Ludwig S
J Virol; 2010 Sep; 84(18):9439-51. PubMed ID: 20592098
[TBL] [Abstract][Full Text] [Related]
8. Ribosomal protein S3 mediates drug resistance of proteasome inhibitor: potential therapeutic application in multiple myeloma.
Chen G; Gao X; Jia X; Wang Y; Xu L; Yu D; Chang S; Deng H; Hu K; Wang G; Li B; Xu Z; Lu Y; Wang H; Zhang T; Song D; Yang G; Wu X; Zhu H; Zhu W; Shi J
Haematologica; 2024 Apr; 109(4):1206-1219. PubMed ID: 37767568
[TBL] [Abstract][Full Text] [Related]
9. A novel 2-iminobenzimidazole compound, XYA1353, displays in vitro and in vivo anti-myeloma activity via targeting NF-κB signaling.
Gao J; Zhou J; Zhang M; Zhang Y; Zeng Y; Li S; Xu K; Yao R
Mol Cell Biochem; 2024 Apr; 479(4):843-857. PubMed ID: 37204666
[TBL] [Abstract][Full Text] [Related]
10. Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors.
Tornatore L; Sandomenico A; Raimondo D; Low C; Rocci A; Tralau-Stewart C; Capece D; D'Andrea D; Bua M; Boyle E; van Duin M; Zoppoli P; Jaxa-Chamiec A; Thotakura AK; Dyson J; Walker BA; Leonardi A; Chambery A; Driessen C; Sonneveld P; Morgan G; Palumbo A; Tramontano A; Rahemtulla A; Ruvo M; Franzoso G
Cancer Cell; 2014 Oct; 26(4):495-508. PubMed ID: 25314077
[TBL] [Abstract][Full Text] [Related]
11. To b(ortezomib) or not to be: the stroma's the thing.
Krem MM; Yan J
J Pathol; 2016 Oct; 240(2):123-5. PubMed ID: 27340009
[TBL] [Abstract][Full Text] [Related]
12. Proteasome Inhibitors in Multiple Myeloma: Biological Insights on Mechanisms of Action or Resistance Informed by Functional Genomics.
Mitsiades CS
Hematol Oncol Clin North Am; 2024 Apr; 38(2):321-336. PubMed ID: 38278626
[TBL] [Abstract][Full Text] [Related]
13. Clinical proof of concept for a safe and effective NF-κB-targeting strategy in multiple myeloma.
Tornatore L; Capece D; D'Andrea D; Begalli F; Verzella D; Bennett J; Acton G; Campbell EA; Kelly J; Tarbit M; Adams N; Bannoo S; Leonardi A; Sandomenico A; Raimondo D; Ruvo M; Chambery A; Oblak M; Al-Obaidi MJ; Kaczmarski RS; Gabriel I; Oakervee HE; Kaiser MF; Wechalekar A; Benjamin R; Apperley JF; Auner HW; Franzoso G
Br J Haematol; 2019 May; 185(3):588-592. PubMed ID: 30255568
[No Abstract] [Full Text] [Related]
14. Novel c-Myc G4 stabilizer EP12 promotes myeloma cytotoxicity by disturbing NF-κB signaling.
Yao R; Zhang Y; Zeng Y; Zhang Y; Liu L; Gao J
Exp Cell Res; 2023 Oct; 431(1):113759. PubMed ID: 37625768
[TBL] [Abstract][Full Text] [Related]
15. PPFIBP1 activates NF-κB signaling to enhance chemoresistance of multiple myeloma.
Deng Y; Chen L; Zhang Q; Xu Y
Transl Oncol; 2023 Nov; 37():101765. PubMed ID: 37619524
[TBL] [Abstract][Full Text] [Related]
16. Multiple Myeloma Inhibitory Activity of Plant Natural Products.
Jöhrer K; Ҫiҫek SS
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34072312
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
Hideshima T; Ikeda H; Chauhan D; Okawa Y; Raje N; Podar K; Mitsiades C; Munshi NC; Richardson PG; Carrasco RD; Anderson KC
Blood; 2009 Jul; 114(5):1046-52. PubMed ID: 19436050
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells.
Markovina S; Callander NS; O'Connor SL; Xu G; Shi Y; Leith CP; Kim K; Trivedi P; Kim J; Hematti P; Miyamoto S
Mol Cancer; 2010 Jul; 9():176. PubMed ID: 20604947
[TBL] [Abstract][Full Text] [Related]
19. Overcoming bortezomib resistance in multiple myeloma.
Murray MY; Auger MJ; Bowles KM
Biochem Soc Trans; 2014 Aug; 42(4):804-8. PubMed ID: 25109961
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of thioredoxin 1 leads to apoptosis in drug-resistant multiple myeloma.
Raninga PV; Di Trapani G; Vuckovic S; Bhatia M; Tonissen KF
Oncotarget; 2015 Jun; 6(17):15410-24. PubMed ID: 25945832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]